|   | |
| Clinical data | |
|---|---|
| Other names | 4-T-MMDA-2; 2-Methoxy-4,5-methylenethiooxyamphetamine; 6-(2-Aminopropyl)-5-methoxy-1,3-benzoxathiol; 4,5-Thiomethyleneoxy-2-methoxyamphetamine; 4-Thio-MMDA-2 | 
| Routes of administration | Oral [1] | 
| Drug class | Psychoactive drug | 
| ATC code | 
 | 
| Pharmacokinetic data | |
| Duration of action | Unknown [1] | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C11H15NO2S | 
| Molar mass | 225.31 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
4T-MMDA-2, also known as 3,4-methylenethiooxy-6-methoxyamphetamine or as 2-methoxy-4,5-methylenethiooxyamphetamine, is a psychoactive drug of the phenethylamine and amphetamine families related to 3,4-methylenedioxyamphetamine (MDA). [1] [2] [3] It is the analogue of MMDA-2 (6-methoxy-MDA) in which one of the oxygen atoms of the methylenedioxy ring, specifically the 4-position oxygen, has been replaced with a sulfur atom. [1] [2] [3]
According to Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), a 4T-MMDA-2 dose of 25 mg orally might be a threshold dose and the active dose is listed as greater than 25 mg. [1] [2] [3] The effects at this "inactive" dose included possible mild exhiliration and a hint of tremor and teeth clenching 3 hours after administration. [1] [3] Higher doses were not explored and the duration is unknown. [1] [2] [3] For comparison, MMDA-2 has a dose of 25 to 50 mg and a duration of 8 to 12 hours. [1] [2] [3]
The effects of 4T-MMDA-2 and various analogues on serotonin and dopamine release in rat brain synaptosomes in vitro were studied by Dennis McKenna and Shulgin and colleagues. [4] 4T-MMDA-2 and MMDA-2 showed essentially abolished monoamine release, in contrast to other related drugs like MDA, MDMA, and MMDA (5-methoxy-MDA), suggesting that 4T-MMDA-2 would not have entactogenic or stimulant effects. [4] The chemical synthesis of 4T-MMDA-2 has been described. [1]
4T-MMDA-2 was first described in the scientific literature by Alexander Shulgin and colleagues in PiHKAL and in a journal article by 1991. [1] [2] [4] [3] It was first tested by Shulgin in 1977. [5]
Two of the methylenedioxyamphetamine compounds have also been similarly modified. The 2-methoxy group of MMDA-3a is replaced with a methylthio group giving 3.4-methylenedioxy-2-methylthioamphetamine, or 2T-MMDA-3a. It is not active at a dosage of 12mg. The second analogue has one of the oxygens of the methylenedioxy group changed to a sulfur. This is 6-(2-aminopropyl)-5-methoxy-l,3-benzoxathiol (4-T-MMDA-2) and it shows no activity at 25mg orally.